254 related articles for article (PubMed ID: 15553394)
1. Pharma goes to the laundry: Public relations and the business of medical education.
Elliott C
Hastings Cent Rep; 2004; 34(5):18-23. PubMed ID: 15553394
[No Abstract] [Full Text] [Related]
2. Pharma PR or medical education?
Roselin JM
Hastings Cent Rep; 2005; 35(2):5-6. PubMed ID: 15957305
[No Abstract] [Full Text] [Related]
3. Pharma PR or medical education?
Rentmeester CA
Hastings Cent Rep; 2005; 35(2):6. PubMed ID: 15957306
[No Abstract] [Full Text] [Related]
4. Pharma PR or medical education?
Sweeney HA
Hastings Cent Rep; 2005; 35(2):4; author reply 5. PubMed ID: 15957304
[No Abstract] [Full Text] [Related]
5. Pharma and CME: View from the US.
Fletcher S
BMJ; 2008 Aug; 337():a1023. PubMed ID: 18703647
[No Abstract] [Full Text] [Related]
6. Industry-Sponsored Speaker Programs-End of the Line?
Adashi EY; Cohen IG
JAMA; 2021 May; 325(18):1835-1836. PubMed ID: 33843960
[No Abstract] [Full Text] [Related]
7. [Code of conduct for psychiatrist - established on behalf of the Austrian Society for Psychiatry and Psychotherapy].
Hinterhuber vH; Lehofer M; Ofner H; Stuppäck C;
Neuropsychiatr; 2009; 23(4):263-6. PubMed ID: 19909698
[No Abstract] [Full Text] [Related]
8. New guidelines expected in 1991 for relationship of continuing education, financial support.
Randall T
JAMA; 1990 Sep; 264(9):1080. PubMed ID: 2384925
[No Abstract] [Full Text] [Related]
9. Perversities--beware of being 'sucked in'.
Bateman C
S Afr Med J; 2009 Apr; 99(4):210, 212. PubMed ID: 19588767
[No Abstract] [Full Text] [Related]
10. Big pharma under the spotlight.
Farham B
S Afr Med J; 2013 May; 103(6):352. PubMed ID: 23725968
[No Abstract] [Full Text] [Related]
11. Marketing Rx&D: one step forward, two steps back.
Yeo M
CMAJ; 2003 May; 168(10):1273-4; discussion 1274-5. PubMed ID: 12743072
[No Abstract] [Full Text] [Related]
12. Sponsored medical education?
Nagral S
Issues Med Ethics; 1998 Jan; 6(1):3. PubMed ID: 16267919
[No Abstract] [Full Text] [Related]
13. Individual wariness needed to spot biased drug research.
Lazarus A
Manag Care; 2005 Sep; 14(9):8, 13. PubMed ID: 16238253
[No Abstract] [Full Text] [Related]
14. Must "no see" always mean a "no know"?
Gamble GL
PM R; 2009 Jan; 1(1):87-8. PubMed ID: 19627879
[No Abstract] [Full Text] [Related]
15. Why do drug companies fear this man?
Simons J
Fortune; 2003 Oct; 148(9):167-8, 170, 172. PubMed ID: 14584310
[No Abstract] [Full Text] [Related]
16. Beyond the naïve "no-see": ethical prescribing and the drive for pharmaceutical transparency.
Oldani M
PM R; 2009 Jan; 1(1):82-6. PubMed ID: 19627878
[No Abstract] [Full Text] [Related]
17. AstraZeneca to pay $355 million fine.
FDA Consum; 2003; 37(5):3. PubMed ID: 14666886
[No Abstract] [Full Text] [Related]
18. The dominance of Big Pharma: unhealthy relationships?
Badcott D; Sahm S
Med Health Care Philos; 2013 May; 16(2):245-7. PubMed ID: 22351151
[No Abstract] [Full Text] [Related]
19. The future sponsorship of CME in Canada: industry, government, physicians or a blend?
Marlow B
CMAJ; 2004 Jul; 171(2):150-1. PubMed ID: 15262885
[No Abstract] [Full Text] [Related]
20. Debate sparked over pharma-funded CME.
Eggertson L
CMAJ; 2016 Mar; 188(4):E65-E66. PubMed ID: 26833734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
